Literature DB >> 18478930

[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].

Yan Wang1, Jian-Ming Xu, Lin Shen, Nong Xu, Jin-Wan Wang, Shun-Chang Jiao, Jing-Sheng Zhang, San-Tai Song, Jian Li, Han-Ying Bao, Lin Yang, Fang Li.   

Abstract

OBJECTIVE: To assess the polymorphism of UGT1A gene in Chinese, and to investigate the correlation between UGT1A polymorphism and irinotecan toxicity in colorectal cancer patients.
METHODS: 70 patients with advanced colorectal cancer were treated with irinotecan and 5-fluorouracil. Polymorphism analysis was performed in all those patients and 100 healthy subjects. Genomic DNA was extracted from peripheral blood and genotyped using polymerase chain reaction and direct sequencing.
RESULTS: 14 patients exhibiting grade 3 - 4 neutropenia (20.0%), 16 patients experienced grade 2 - 4 diarrhea (22.9%), including only 4 patients with grade 3 - 4 diarrhea (5.7%). Compared with TA6/7 and TA7/7, UGT1 A1 * 28 wild genotype TA6/6 was significantly associated with reduced toxicity (42.1% vs. 15.7%, P = 0.027). There was no significant difference in the distribution of UGT1A genotypes between colorectal cancer patients and healthy subjects.
CONCLUSION: Chinese patients exhibit less irinotecan-related diarrhea due to higher frequence of UGT1A A1 * 28 wild genotype TA6/6.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18478930

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  5 in total

1.  Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.

Authors:  Xun Cai; Chuan Tian; Liwei Wang; Rongyuan Zhuang; Xiaowei Zhang; Yuanbiao Guo; Hongmin Lu; Hui Wang; Xiaoyu Li; Junwei Gao; Qi Li; Chungang Wang
Journal:  Cancer Biol Ther       Date:  2017-02-17       Impact factor: 4.742

2.  UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.

Authors:  Yan Wang; Lin Shen; Nong Xu; Jin-Wan Wang; Shun-Chang Jiao; Ze-Yuan Liu; Jian-Ming Xu
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

3.  Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.

Authors:  Xing-Han Liu; Jun Lu; Wei Duan; Zhi-Ming Dai; Meng Wang; Shuai Lin; Peng-Tao Yang; Tian Tian; Kang Liu; Yu-Yao Zhu; Yi Zheng; Qian-Wen Sheng; Zhi-Jun Dai
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

4.  Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1*6 or UGT1A1*28.

Authors:  Chuan Tian; Haifeng Ying; Rongyuan Zhuang; Xiaowei Zhang; Hongmin Lu; Hui Wang; Shuowen Wang; Qi Li; Chungang Wang; Xun Cai
Journal:  Cancer Manag Res       Date:  2018-11-22       Impact factor: 3.989

5.  Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer.

Authors:  Hongyang Lu; Jing Qin; Na Han; Fajun Xie; Lei Gong; Chenghui Li
Journal:  Integr Cancer Ther       Date:  2018-09-19       Impact factor: 3.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.